News
Bayer’s Xarelto approved in the UK
Bayer’s oral factor Xa inhibitor Xarelto (rivaroxaban) has been approved in the UK to treat venous thromboembolism (VTE) and to prevent VTE recurrence in children.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Bayer’s oral factor Xa inhibitor Xarelto (rivaroxaban) has been approved in the UK to treat venous thromboembolism (VTE) and to prevent VTE recurrence in children.